CWBR cheap anti-aging stockCWBR CohBar is a clinical stage biotechnology company which develops mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases.
CWBR closed few months ago a $15.0 Million Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now.
Cantor Fitzgerald brokerage has a $2.5 price target for it.
Cohbar
CWBR Upside PotentialCWBR closed 2 months ago a $15.0 Million Public Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now.
On the other hand, Cantor Fitzgerald brokerage has a $2.5 price target for it.
52 Week Range 0.34 - 2.27 Just bounced from its lowest support.
CWBR antiaging stock Price Target I think antiaging stocks will be the new FAANGS in 5 to 10 years.
Immortality here, on earth, is the next frontier for the medicine.
CohBar is developing mitochondria-based therapeutics for the treatment of chronic and age-related diseases.
On 11/12/2021 Cantor Fitzgerald brokerage Initiated Coverage on CWBR with an Overweight rating and a price target of $2.50.
This all time low looks like a great buy opportunity for me.
Looking forward to read your opinion on it.
CWBR CohBar retracement completed ! Buy opportunity? CWBR CohBar is developing mitochondria based therapeutics for the treatment of age-related diseases.
So it`s an anti-aging listed companies.
They released positive topline results from an early stage study into CB4211, a drug under development for the treatment of nonalcoholic steatohepatitis, but after a 70% increase, the stock went even lower than before the pump.
WBB Securities upgraded CohBar, Inc. stock to Buy from Speculative Buy with a price target of $5.
On 4/23/2021 Maxim Group brokerage Initiated Coverage with a Buy rating and a price target of $3.00
The Market Cap is only 72.138M
I see a lot of potential in this stock! Do you?
CWBR Cohbar Anti-aging Stock Upside PotentialIf you didn`t bought the stock at my first signal, now you can have a second chance, but 14% more expensive:
I think anti-aging stocks will be the next big thing of this decade.
Top Institutional Holders:
Blackrock Inc . 1,179,131 shares on Jun 29, 2020 worth 1,827,653 usd
Vanguard Group, Inc. 971,649 shares on Jun 29, 2020 worth 1,506,055 usd
Millennium Management LLC 362,116 shares on Jun 29, 2020 561,279 usd
On 9/17/2020 Roth Capital brokerage Initiated Coverage rating Buy with a target of $8.00.
Only 58Mil market cap
Chief Executive Officer, Steven Engle, will present a company update at the BIO Investor Forum, being held virtually on October 13-15, 2020.
Cohbar develops treatments that have widespread potential to target diseases related to aging and metabolic dysfunction, such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular diseases and central nervous system conditions.
In May, the company initiated testing of CB5064 analogs that interact with the apelin receptor in preclinical models of ARDS to assess their potential as therapeutics for COVID-19 associated ARDS.
Chief Executive Officer will be a participant on the panel titled “Emerging Companies” at the Targeting Metabesity Conference, being held virtually on October 12-15, 2020.
If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
